DXC
(3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID
Created: | 2000-06-26 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 68 |
Chiral Atom Count | 10 |
Bond Count | 71 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | (3ALPHA,5BETA,12ALPHA)-3,12-DIHYDROXYCHOLAN-24-OIC ACID |
Synonyms | DEOXYCHOLIC ACID |
Systematic Name (OpenEye OEToolkits) | (4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
Formula | C24 H40 O4 |
Molecular Weight | 392.572 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(O)CCC(C4CCC3C2C(C1(C)CCC(O)CC1CC2)CC(O)C34C)C |
SMILES | CACTVS | 3.341 | C[CH](CCC(O)=O)[CH]1CC[CH]2[CH]3CC[CH]4C[CH](O)CC[C]4(C)[CH]3C[CH](O)[C]12C |
SMILES | OpenEye OEToolkits | 1.5.0 | CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C |
Canonical SMILES | CACTVS | 3.341 | C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C |
InChI | InChI | 1.03 | InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1 |
InChIKey | InChI | 1.03 | KXGVEGMKQFWNSR-LLQZFEROSA-N |
Drug Info: DrugBank
DrugBank ID | DB03619 |
---|---|
Name | Deoxycholic acid |
Groups | approved |
Description | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical procedures. |
Synonyms |
|
Brand Names |
|
Indication | For improvement in appearance of moderate to severe fullness associated with submental fat in adults. |
Categories |
|
ATC-Code | D11AX24 |
CAS number | 83-44-3 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Steroid Delta-isomerase | MNLPTAQEVQGLMARYIELVDVGDIEAIVQMYADDATVEDPFGQPPIHGR... | unknown | |
PpcA | MKKVIASLALSVFCAGLAFAADDIVLKAKNGDVKFPHKAHQKAVPDCKKC... | unknown | |
Elongation factor Tu GTP-binding domain-containing protein 1 | MVLNSLDKMIQLQKNTANIRNICVLAHVDHGKTTLADCLISSNGIISSRL... | unknown | |
Choloylglycine hydrolase | MCTGLALETKDGLHLFGRNMDIEYSFNQSIIFIPRNFKCVNKSNKKELTT... | unknown | |
Lactaldehyde dehydrogenase | MSVPVQHPMYIDGQFVTWRGDAWIDVVNPATEAVISRIPDGQAEDARKAI... | unknown | |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 222528 |
ChEMBL | CHEMBL406393 |
ChEBI | CHEBI:28834 |
CCDC/CSD | SORXED, RAVVUF, YOMKAN, FEHYAS02, FEHYAS03, TOFBUO, BARPUG, FEHYAS01, DADKUP, TOFBOI, FEHYAS04, YECPUT, UBOCOF, QQQDFA01, DANSEQ, PEJBOW |
COD | 2006240, 4501232, 7203350, 7216029 |